Page 225 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 225
YI P0614 KEY HBSAG MUTATIONS SIGNIFICANTLY CORRELATE ePOSTERS
WITH HCC, HAMPER HBSAG SECRETION AND PROMOTE
YI P0615 CELL PROLIFERATION INVITRO
YI P0616 Matteo Surdo*, Romina Salpini, Nadia Warner, Maria F. Cortese,
YI P0617 Carmen Mirabelli, Danni Colledge, Sally Soppe, Michela Pollicita,
YI P0618 Roberta Longo, Sara Romano, Giuseppina Cappiello, Alberto Spanò,
Pascale Trimoulet, Henry Fleury, Jacopo Vecchiet, Nerio Iapadre,
Angelo Barlattani, Ada Bertoli, Terenzio Mari, Caterina Pasquazzi,
Gabriele Missale, Cesare Sarrecchia, Elisa Orecchini,
Alessandro Michienzi, Massimo Andreoni, Simona Francioso,
Mario Angelico, Francesca Ceccherini-Silberstein, Stephen Locarnini,
Carlo-Federico Perno, Valentina Svicher, Italy
DIAGNOSIS BY SCREENING RATHER THAN SYMPTOMS
IN HBV-RELATED HCC IS ASSOCIATED WITH IMPROVED
OUTCOMES, REGARDLESS OF CIRRHOSIS STATUS BUT
SCREENING HISTORY WAS ONLY PRESENT IN ONE-HALF
OF CIRRHOSIS AND ONE-THIRD OF NONCIRRHOSIS
CASES
Vincent L. Chen*, Lily Kim, Pauline Nguyen, Changqing Zhao,
Mindie H. Nguyen, The United States
DESIGNING ENHANCED PATHWAYS OF CARE FOR
PATIENTS WITH CHRONIC HEPATITIS B USING HEPBASE,
A PROPRIETARY DATABASE USED TO STRATIFY PATIENTS
Ankur Srivastava*, Paul Trembling, Sudeep Tanwar, Janet Catt,
Zareen Mehboob, Dominic Morgan, Geoffrey Dusheiko,
William Rosenberg, The United Kingdom
IS HBEAG SEROCONVERSION A VALID SURROGATE
MARKER FOR TRANSPLANT-FREE SURVIVAL IN CHRONIC
HEPATITIS B PATIENTS TREATED WITH LAMIVUDINE OR
ENTECAVIR?
Jihyun An*,Young-Suk Lim, Hwa-Jung Kim, Dong Jin Suh, South Korea
ANTI-HEV IGG SEROPREVALENCE IN EUROPE: A META-
ANALYSIS
Johannes Hartl*, K L Woolson, G Webb, M Saunders, Ansgar W Lohse,
H D Dalton, Sven Pischke, Germany
Vienna, Austria • April 22–26, 2015 225
WITH HCC, HAMPER HBSAG SECRETION AND PROMOTE
YI P0615 CELL PROLIFERATION INVITRO
YI P0616 Matteo Surdo*, Romina Salpini, Nadia Warner, Maria F. Cortese,
YI P0617 Carmen Mirabelli, Danni Colledge, Sally Soppe, Michela Pollicita,
YI P0618 Roberta Longo, Sara Romano, Giuseppina Cappiello, Alberto Spanò,
Pascale Trimoulet, Henry Fleury, Jacopo Vecchiet, Nerio Iapadre,
Angelo Barlattani, Ada Bertoli, Terenzio Mari, Caterina Pasquazzi,
Gabriele Missale, Cesare Sarrecchia, Elisa Orecchini,
Alessandro Michienzi, Massimo Andreoni, Simona Francioso,
Mario Angelico, Francesca Ceccherini-Silberstein, Stephen Locarnini,
Carlo-Federico Perno, Valentina Svicher, Italy
DIAGNOSIS BY SCREENING RATHER THAN SYMPTOMS
IN HBV-RELATED HCC IS ASSOCIATED WITH IMPROVED
OUTCOMES, REGARDLESS OF CIRRHOSIS STATUS BUT
SCREENING HISTORY WAS ONLY PRESENT IN ONE-HALF
OF CIRRHOSIS AND ONE-THIRD OF NONCIRRHOSIS
CASES
Vincent L. Chen*, Lily Kim, Pauline Nguyen, Changqing Zhao,
Mindie H. Nguyen, The United States
DESIGNING ENHANCED PATHWAYS OF CARE FOR
PATIENTS WITH CHRONIC HEPATITIS B USING HEPBASE,
A PROPRIETARY DATABASE USED TO STRATIFY PATIENTS
Ankur Srivastava*, Paul Trembling, Sudeep Tanwar, Janet Catt,
Zareen Mehboob, Dominic Morgan, Geoffrey Dusheiko,
William Rosenberg, The United Kingdom
IS HBEAG SEROCONVERSION A VALID SURROGATE
MARKER FOR TRANSPLANT-FREE SURVIVAL IN CHRONIC
HEPATITIS B PATIENTS TREATED WITH LAMIVUDINE OR
ENTECAVIR?
Jihyun An*,Young-Suk Lim, Hwa-Jung Kim, Dong Jin Suh, South Korea
ANTI-HEV IGG SEROPREVALENCE IN EUROPE: A META-
ANALYSIS
Johannes Hartl*, K L Woolson, G Webb, M Saunders, Ansgar W Lohse,
H D Dalton, Sven Pischke, Germany
Vienna, Austria • April 22–26, 2015 225
